Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

77.65
-0.7200-0.92%
Volume:998.54K
Turnover:78.17M
Market Cap:12.58B
PE:-48.13
High:79.49
Open:78.75
Low:77.45
Close:78.37
52wk High:83.61
52wk Low:23.95
Shares:161.97M
Float Shares:161.00M
Volume Ratio:0.51
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6132
EPS(LYR):-3.0358
ROE:-40.04%
ROA:-5.68%
PB:20.35
PE(LYR):-25.58

Loading ...

Ionis Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
Yesterday

RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Is It Too Late to Consider Ionis After Its 126% Surge in 2025?

Simply Wall St.
·
Yesterday

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Dec 16

Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $100 From $85

THOMSON REUTERS
·
Dec 15

Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Strong 1-Year Share Price Surge

Simply Wall St.
·
Dec 10

Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 10

Ionis Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $97 From $86

THOMSON REUTERS
·
Dec 09

Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares

Reuters
·
Dec 04

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Reuters
·
Dec 02

Ionis Receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease (Axd)

THOMSON REUTERS
·
Dec 02

Ionis Pharmaceuticals Inc - on Track to Submit Nda for Zilganersen in Q1 2026

THOMSON REUTERS
·
Dec 02

Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen

Simply Wall St.
·
Dec 02

Ionis Pharmaceuticals Shares Reverse Premarket Course, Last Down 2.4%

THOMSON REUTERS
·
Dec 01

Ionis Pharmaceuticals Shares up 3.5% Premarket After Co Receives FDA Breakthrough Therapy Designation for Olezarsen for Shtg

THOMSON REUTERS
·
Dec 01

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Olezarsen for Severe Hypertriglyceridemia

Reuters
·
Dec 01

Ionis Pharmaceuticals Inc: on Track to Submit Supplemental New Drug Application by End of Year

THOMSON REUTERS
·
Dec 01

Ionis Receives U.S. FDA Breakthrough Therapy Designation for Olezarsen for Severe Hypertriglyceridemia (Shtg)

THOMSON REUTERS
·
Dec 01

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

GlobeNewswire
·
Dec 01